MarketCap
Facebook
X
Telegram
Affimed N.V. Total Assets | AFMD
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Affimed N.V.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 97.2 M | 201 M | 225 M | 176 M | 112 M | 116 M | 43.2 M | 48.7 M | 79.3 M | 41.9 M | 6.5 M | 7.2 M | - |
Annual performance
Select metrics to display
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 225 M | 6.5 M | 96.2 M |
Quarterly Total Assets Affimed N.V.
| 2024-Q2 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 53.2 M | 97.2 M | - | 135 M | - | - | 261 M | - | 225 M | - | 248 M | - | 176 M | - | 101 M | - | 112 M | - | 99.1 M | - | 116 M | - | - | - | 43.2 M | - | - | - | 48.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 261 M | 43.2 M | 132 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M |  USA |
 |
Applied Therapeutics
APLT
|
86.7 M | - | - | $ 8.42 M | USA |
 |
ESSA Pharma
EPIX
|
128 M | - | - | $ 8.86 M |  Canada |
 |
Generation Bio Co.
GBIO
|
231 M | - | - | $ 344 M | USA |
 |
Clearside Biomedical
CLSD
|
25.1 M | - | - | $ 25.3 M | USA |
 |
Merus N.V.
MRUS
|
783 M | - | - | $ 5.78 B |  Niderland |
 |
RAPT Therapeutics
RAPT
|
240 M | - | - | $ 2.36 B | USA |
 |
Annexon
ANNX
|
278 M | $ 4.2 | -0.36 % | $ 651 M | USA |
 |
AbbVie
ABBV
|
134 B | $ 294.72 | 0.32 % | $ 521 B | USA |
 |
Galmed Pharmaceuticals Ltd.
GLMD
|
18.6 M | $ 4.63 | 21.05 % | $ 20 M |  Israel |
 |
Avenue Therapeutics
ATXI
|
2.93 M | - | -52.27 % | $ 4.45 M | USA |
 |
Achieve Life Sciences
ACHV
|
41.8 M | $ 6.78 | 0.89 % | $ 296 M | USA |
 |
Axon Enterprise
AXON
|
7 B | $ 316.97 | 4.77 % | $ 24.7 B | USA |
 |
TFF Pharmaceuticals
TFFP
|
12 M | - | -60.05 % | $ 125 K | USA |
 |
Bristol-Myers Squibb Company
BMY
|
90 B | $ 62.89 | 0.18 % | $ 128 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
246 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Axcella Health
AXLA
|
18.9 M | - | -16.42 % | $ 249 M | USA |
 |
Cytokinetics, Incorporated
CYTK
|
1.42 B | $ 58.59 | 4.29 % | $ 7.04 M | USA |
 |
Dynavax Technologies Corporation
DVAX
|
986 M | - | - | $ 2.02 B | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.97 B | $ 159.75 | 5.35 % | $ 20.9 B | USA |
 |
Amgen
AMGN
|
90.6 B | $ 467.97 | 0.59 % | $ 252 B | USA |
 |
Orgenesis
ORGS
|
1.35 M | - | -33.86 % | $ 61.2 M | USA |
 |
Codiak BioSciences
CDAK
|
172 M | - | -55.98 % | $ 2.15 M | USA |
 |
Jazz Pharmaceuticals plc
JAZZ
|
11.7 B | $ 248.31 | 1.17 % | $ 15.1 B |  Irlanda |
 |
Johnson & Johnson
JNJ
|
199 B | $ 280.31 | -0.17 % | $ 675 B | USA |
 |
Kala Pharmaceuticals
KALA
|
9.49 M | $ 0.17 | 0.64 % | $ 1.39 M | USA |
 |
BioLineRx Ltd.
BLRX
|
40.9 M | $ 1.49 | -1.97 % | $ 3.67 B | Israel |
 |
Sage Therapeutics
SAGE
|
547 M | - | - | $ 527 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
9.51 M | $ 1.59 | -2.76 % | $ 2.62 M | Israel |
 |
Lineage Cell Therapeutics
LCTX
|
113 M | $ 1.13 | 8.17 % | $ 260 M | USA |
 |
Paratek Pharmaceuticals
PRTK
|
173 M | - | - | $ 121 M | USA |
 |
TCR2 Therapeutics
TCRR
|
208 M | - | - | $ 58.1 M | USA |
 |
C4 Therapeutics
CCCC
|
359 M | $ 2.9 | -3.5 % | $ 240 M | USA |
 |
Eli Lilly and Company
LLY
|
112 B | $ 1 437.4 | 0.36 % | $ 1.29 T | USA |
 |
ASLAN Pharmaceuticals Limited
ASLN
|
24.6 M | - | -14.27 % | $ 1.7 M |  Singapore |
 |
Compugen Ltd.
CGEN
|
157 M | $ 2.09 | -0.24 % | $ 195 M | Israel |
 |
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | USA |
 |
Crinetics Pharmaceuticals
CRNX
|
1.13 B | $ 84.95 | 0.13 % | $ 7.99 B | USA |
 |
GeoVax Labs
GOVX
|
6.34 M | $ 2.13 | -20.4 % | $ 2.04 M | USA |
 |
Unity Biotechnology
UBX
|
37.7 M | - | -33.41 % | $ 3.37 M | USA |
 |
MediciNova
MNOV
|
45.6 M | $ 1.41 | 0.36 % | $ 69.2 M | USA |
 |
AVEO Pharmaceuticals
AVEO
|
105 M | - | - | $ 521 M | USA |
 |
Seelos Therapeutics
SEEL
|
5.42 M | - | -47.76 % | $ 6.27 M | USA |
 |
Celldex Therapeutics
CLDX
|
583 M | $ 30.18 | -1.53 % | $ 2 B | USA |
 |
Moderna
MRNA
|
12.3 B | $ 248.62 | -0.88 % | $ 96.7 B | USA |
 |
CollPlant Biotechnologies Ltd.
CLGN
|
10.8 M | $ 3.96 | 1.41 % | $ 48.3 M | Israel |
 |
Kiromic BioPharma
KRBP
|
8.54 M | - | 6.61 % | $ 3.08 M | USA |
 |
Nektar Therapeutics
NKTR
|
280 M | $ 38.41 | 1.67 % | $ 648 M | USA |
|
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | USA |
 |
CorMedix
CRMD
|
826 M | $ 5.31 | -2.23 % | $ 383 K | USA |